An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer
Sponsor study identifier
Secondary identifiers
REGISTRY · PDQ (Physician Data Query)
interventional
N/A
0 countries
N/A
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
April 2004
Actual (reported)RATIONALE: Epoetin alfa may stimulate red blood cell production to treat patients who have anemia following chemotherapy. PURPOSE: Phase IV trial to study the effectiveness of epoetin alfa in treating chemotherapy-related anemia in women who have stage I, stage II, or stage III breast cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 2004
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 10, 2001
Actual (reported)April 2004
Actual (reported)April 5, 2004
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
John A. Glaspy, MD, MPH
Jonsson Comprehensive Cancer Center
First Submitted
August 10, 2001
First Posted
April 5, 2004
Study Completion
April 2004
Actual (reported)Last Updated
July 18, 2013
Record last verified: 2002-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.